Cancer-related cognitive impairment (CRCI) is cognitive symptoms, such as impairment of memory, attention, executive functions, and processing speed, elicited by some chemotherapy and hormonal treatment in many of cancer patients and survivors. Because CRCI impairs patientsʼ quality of life during and after cancer but there is no effective prevention and treatment for this side effect, CRCI is a significant medical problem. In this study, we explored which drugs for cancer treatment is related to cognitive impairment using the FDA Adverse Event Reporting System (FAERS), the worldʼs largest freely available self-reported adverse events database, and validated the effect of the candidate drugs conducting in vivo behavioral experiments. FAERS analysis revealed that the use of some hormone-modulating drugs showed strong associations with the occurrence of cognitive impairment. We further observed cognitive impairment in mice administered with one of the hormone-modulating candidates on day 1 and 7 but not on day 14 in novel object recognition test. Further experiments will be needed to elucidate the pathophysiological mechanism in hormone-modulating drugs-induced cognitive impairment and to develop effective preventive/therapeutic approach for CRCI related to hormonal treatment.